

Performance in Delivering Clinical Trials - Q3 2018/19

Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed	Maximum Number Of Patients Agreed	Target Date To Recruit Patients Agreed?	Date agreed to recruit target number of participants	Total Number Of patients Recruited at the agreed date	Total Number Of Study Participants Recruited	Date that the trial closed to recruitment	Reason For Closure Of Trial
16/EE/0358	212839	A randomized, blinded, parallel group, multi-center dose-finding study, to assess the efficacy, safety and tolerability of different doses of tobramycin inhalation powder in patients with Non-Cystic Fibrosis Bronchiectasis and pulmonary P. aeruginosa	Range Agreed	2	3	Date Agreed	01/03/2019	2	2	31/08/2018	Withdrawn By Sponsor
17/EE/0502	218716	Long-term, open label, multicenter, extension study to evaluate the safety and tolerability of QCC374 in patients with PAH	Number Agreed	2	2	Date Agreed	05/09/2018	2	2	05/09/2018	Recruitment Finished
18/NE/0104	241180	A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)	Number Agreed	1	1	Date Agreed	31/08/2018	2	2	31/08/2018	Recruitment Finished
18/NW/0006	237093	Assessment of safety, tolerability, pharmacokinetics and pharmacodynamics of multiple oral doses of the combination of GLPG2451 and GLPG2222, with or without GLPG2737, in adult subjects with cystic fibrosis	Number Agreed	2	2	Date Agreed	25/05/2019	0	0	31/07/2018	Recruitment Finished
17/EE/0472	235110	BAROSTIM NEO - Baroreflex Activation Therapy for Heart Failure	Number Agreed	8	8	Date Agreed	01/12/2019	1	1	23/10/2018	Withdrawn By Sponsor
17/SC/0025	213874	A Prospective, Randomized, Open-Label, Blinded Endpoint Evaluation (PROBE) Parallel Group Study Comparing Edoxaban vs. VKA in Subjects Undergoing Catheter Ablation of Non-valvular Atrial Fibrillation (ELIMINATE-AF).	Number Agreed	3	3	Date Agreed	30/06/2018	0	0	11/04/2018	Withdrawn By Host
17/NE/0115	218417	MULTICENTER, INTERNATIONAL, DOUBLEBLIND, TWO-ARM, RANDOMIZED, PLACEBOCONTROLLED PHASE II TRIAL OF PIRFENIDONE IN PATIENTS WITH UNCLASSIFIABLE PROGRESSIVE FIBROSING ILD	Number Agreed	2	2	Date Agreed	01/04/2018	3	3	04/04/2018	Recruitment Finished
16/SC/0436	211806	A Double-Blind, Placebo-Controlled, Randomized-Withdrawal, Multicenter Study of the Efficacy and Safety of JZP-258 in Subjects with Narcolepsy with Cataplexy	Number Agreed	4	4	Date Agreed	19/10/2018	1	1	24/08/2018	Recruitment Finished
16/LO/1424	207336	A Phase 2a, Randomized, Double-blind, Placebocontrolled, Incomplete	Range Agreed	1	5	Date Agreed	04/04/2018	1	1	31/05/2018	Recruitment Finished